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Understanding the structure-function relationships
at cellular, circuit, and organ-wide scale requires
3D anatomical and phenotypical maps, currently un-
available for many organs across species. At the root
of this knowledge gap is the absence of a method
that enables whole-organ imaging. Herein, we pre-
sent techniques for tissue clearing in which whole
organs and bodies are rendered macromolecule-
permeable and optically transparent, thereby
exposing their cellular structure with intact connec-
tivity. We describe PACT (passive clarity technique),
a protocol for passive tissue clearing and immuno-
staining of intact organs; RIMS (refractive index
matching solution), a mounting media for imaging
thick tissue; and PARS (perfusion-assisted agent
release in situ), a method for whole-body clearing
and immunolabeling. We show that in rodents
PACT, RIMS, and PARS are compatible with endog-
enous-fluorescence, immunohistochemistry, RNA
single-molecule FISH, long-term storage, and micro-
scopy with cellular and subcellular resolution. These
methods are applicable for high-resolution, high-
content mapping and phenotyping of normal and
pathological elements within intact organs and
bodies.INTRODUCTION
Facile and physiologically informative optical access to intact
tissues has long been a goal of biologists. As early as the
1800s, work by scientists such as Werner Spalteholz revealed
the utility of rendering tissue optically transparent for anatom-
ical and biomedical studies (Spalteholz, 1914). Although the
Spalteholz technique and its variants incur damage to tissue
integrity and morphology, they are still in use a century later
(Steinke and Wolff, 2001), highlighting barriers to the adoptionof more recent tissue-clearing methods and modern micro-
scopy techniques. While separate tissue-clearing protocols
have strengths in an application-specific context, none is
able to fully surmount the most common obstacles: uncon-
firmed generalizability across organs other than the brain or
embryo, difficulties in execution, and incompatibility with
endogenous fluorescence and/or post hoc immunohistochem-
istry (Table S1). Thus motivation to improve tissue-clearing
protocols is sustained around three main objectives: (1) effi-
cient clearing of both central organs and peripheral tissue (2)
preservation of cellular and subcellular structures of multiple
organ types; and (3) compatibility with endogenous fluorescent
protein expression and post hoc detection of DNA, RNA, and
peptides.
The payoffs of such a method are optical access throughout
large volumes of tissues, enabling the study of cell-to-cell spatial
relationships and long-range neural connectivity in the context of
preserved tissue morphology (Chung and Deisseroth, 2013;
Chung et al., 2013; Kim et al., 2013; Zhang et al., 2014). In
conjunction with fluorescent tracers, tissue clearing facilitates
the identification of interacting cellular structures, including
diverging or converging nerves and vasculature at their target
sites throughout the body. Fine-scale subcellular analysis of
cleared specimens using standard protein and nucleic acid
probes should also be achievable in the context of cleared
tissues.
We have developed a methodology for whole-organism
clearing, building upon previous techniques such as CLARITY,
SCALE, SeeDB, ClearT, 3DISCO, CUBIC, dibenzyl ether (DBE),
and BABB (Murray’s Clear) (Becker et al., 2012; Chung et al.,
2013; Dodt et al., 2007; Ertu¨rk et al., 2012a; Hama et al., 2011;
Ke et al., 2013; Kuwajima et al., 2013; Susaki et al., 2014).
Each of these has made a clear contribution: hydrogel embed-
ding to stabilize tissue structures (Chung et al., 2013), fluores-
cent protein-compatible clearing reagents (Susaki et al., 2014),
and imaging approaches for large or challenging tissue sam-
ples (Becker et al., 2013; Tseng et al., 2009; Tomer et al.,
2014). Although a comprehensive discussion of their respec-
tive strengths and weaknesses is beyond the scope of this
text, a few critical points merit mention. First, in the original
proof of principle for each of these techniques, the detailedCell 158, 945–958, August 14, 2014 ª2014 Elsevier Inc. 945
Figure 1. PACT Clearing of A4P0 Tissue-Hydrogel Hybrid Achieves Optimal Transparency and Immunohistochemistry Compatibility across
Organs
(A) Optical transparency comparison of 3 mm adult mouse sagittal blocks of A2P0, A4P0, and A4P4 tissue-hydrogel hybrid cleared for 24 hr and 48 hr.
(B) Compared to A4P4, A4P0 tissue-hydrogel hybrid showed faster antibody penetration (n = 6 fields of view per sample).
(C) The percentage of protein loss from1 mm mouse brain slices (n = 6 slices for each clearing condition); statistical significance is shown for each condition
versus A4P0 8% SDS (red).
(D) The integrated eYFP fluorescence intensity in arbitrary units (A.U.) of uncleared and cleared 1 mm Thy1-eYFP mouse brain slices (n = 6 slices).
(E) Compared to A4P4, the A4P0 hydrogel-tissue hybrid showed higher tissue expansion and weight gain postclearing.
(legend continued on next page)
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methods and optimized protocols were only presented for
clearing brain tissue, and occasionally for the spinal cord
(Ertu¨rk et al., 2012a; Zhang et al., 2014) or whole embryo
(Dodt et al., 2007; Hama et al., 2011). 3DISCO represents, to
date, the most complete elucidation of a clearing method
across different tissues. However, as is the case with many
prior clearing protocols (Table S1 available online), 3DISCO’s
clearing reagents (tetrahydrofuran and DBE) substantially
quench fluorescent signals in tissue samples (Ertu¨rk et al.,
2012a). CLARITY (Chung et al., 2013) and CUBIC (Susaki
et al., 2014) bypass the fluorescence quenching problem,
but CLARITY in its original form used electrophoretic tissue
clearing (ETC) to extract lipids from large samples, which
can be challenging to implement and can cause variability
in final tissue quality, including epitope loss, damage to fine
processes, and tissue browning due to heating (forum.
claritytechniques.org). This has led to variations of CLARITY
using passive lipid extraction (Zhang et al., 2014, with protocol
described in detail in Tomer et al., 2014, along with thermal
acceleration of clearing and improved imaging). CUBIC also
achieves tissue transparency by passively clearing phospho-
lipids and is compatible with hydrogel embedding. The main
weakness of passive clearing methods is their slow speed,
which makes them unsuited for clearing large tissue volumes
or whole organisms.
Herein, we propose a methodology to facilitate fast, whole-
brain and whole-body clearing using systemic or cerebrospinal
circulation to directly deliver clarifying agents. A first step was
to optimize the hydrogel embedding, clearing, and imaging
reagents, which resulted in PACT, for passive clarity tech-
nique, for quicker passive lipid extraction of 1- to 3-mm-thick
tissues. To image PACT-cleared tissue we have developed a
refractive index matching solution (RIMS)—a custom econom-
ical recipe, with outcome similar to FocusClear (Chung et al.,
2013; Moy et al., 2013; Tseng et al., 2009). The PACT reagents
may be delivered either intracranially or via the vasculature
to achieve whole-brain and -body clearing and labeling. We
term the latter PARS, for perfusion-assisted agent release in
situ. All steps for PARS, including preservation, clearing, and
labeling, are performed in situ prior to tissue extraction.
We demonstrate below that PARS, together with RIMS, trans-
form opaque, intact, whole-organisms into optically trans-
parent, fluorescently labeled samples for visualization with
conventional confocal microscopy and phenotypic analysis at
the cellular, subcellular, and even single-molecule transcripts
level.(F–H) Thy1-eYFP mouse sections stained with Nissl: (F) 1 mm cleared brain slice
uncleared brain slice, PFC (left: z = 100 mm imaging stack depth); (H) 1 mm spin
(I) Substantia nigra pars compacta (SNc) of 1 mm mouse brain slice stained with
(J) PFC of 1 mm adult mouse brain slices stained with antibodies against GFAP,
(K) 1 mm section of mouse kidney (z = 150 mm; arrowheads show glomeruli), h
(z = 350 mm) stained with anti-integrin antibodies, SYTO24, and acridine orange.
(L) 3-mm-thick PACT-cleared human tissue biopsy from basal cell carcinoma (B
antibody and counterstained with DAPI to label endothelial cells (700 mm imagin
All graphs are shown inmean ± SEM. Statistical significance: for paired samples: 2
Bonferroni post hoc (*p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.0001). Objecti
H, J, and K) LD LCI Plan-Apochromat 253/0.8 Imm Corr DIC M27 multi-immers
mersion objective; (L) Zeiss Plan-Apochromat 103/0.45 objective. Also see FiguRESULTS
Optimized Method for Passive Clearing and
Immunostaining of Whole Organs in the Rodent
Similar to the CLARITY method (Chung et al., 2013; Tomer et al.,
2014), we render thick tissue optically transparent for imaging in
three main steps. First, tissue is crosslinked and hybridized to
hydrogel monomers to stabilize biomacromolecules. Second,
tissue lipids are extracted from the tissue-hydrogel matrix with
ionic detergents. Third, cleared tissue is embedded in RIMS for
imaging, or for long-term storage. Although whole-body clearing
was our primary goal, we recognized that the processing of small
or particularly fragile specimens and organs would best be
accomplished by a mild, passive clearing protocol. We devel-
oped PACT for rendering rodent whole organs, their 1- to
3-mm-thick sections, including brain, spinal cord, kidney, heart,
lung, and intestine, or human tissue biopsies transparent. The
clearing speed depends in part on the rate of lipid solvation by
detergent micelles, and the rate of diffusion of detergent micelles
in tissue (Hoffman, 2002). However, unless an applied force
accelerates their diffusion through tissue, such as the electric
field in CLARITY’s ETC (Chung et al., 2013; Tomer et al., 2014),
lipid extraction by large micelles is slow. We tested different
detergents at various concentrations for their ability to passively
clear 3 mm coronal mouse brain blocks over a 3 day incuba-
tion. Sodium dodecyl sulfate (SDS) at all concentrations was
superior for lipid solvation and removal from brain tissue to other
detergents, and moreover, only the 8% SDS concentration
achieved uniform clearing throughout the entire 3 mm block
(Figure S1A).
We hypothesized that a decrease in the crosslink density of
the tissue-hydrogel would facilitate both lipid extraction and
macromolecule penetration into thick, highly myelinated or
fibrous tissue during subsequent immunohistochemistry. To
test this, 3 mm brain sections were infused with varying combi-
nations and concentrations of formaldehyde, acrylamide, and
bis-acrylamide, degassed, and polymerized at 37C. The effi-
ciency of tissue clearing (Figure 1A) and the depth of antibody
penetration (Figure 1B) increased significantly when lower con-
centrations of formaldehyde and acrylamide were used and
when bis-acrylamide, an acrylamide crosslinking agent used in
CLARITY (Tomer et al., 2014), was excluded from the cocktail
of hydrogel monomers. Upon observing a qualitative increase
in tissue transparency in the tissue-hydrogels prepared with
lower acrylamide concentrations (Figure 1A), we assayed the
different PACT tissue preparations for protein loss, tissue, prefrontal cortex (PFC) area (left: z = 1 mm imaging stack depth); (G) 100 mm
al cord slice (z = 500 mm).
anti-tyrosine hydroxylase (TH) antibody (z = 1 mm).
mouse-IgG, and Iba1 (z = 500 mm).
eart (z = 320 mm), lung (z = 550 mm), and 400 mm section of mouse intestine
CC) was stained with anti-pan-cytokeratin (AE1/AE3) Alexa Fluor 488 primary
g stack depth).
-tailed Student’s t test; for multiple comparisons: one-way ANOVA followed by
ves used for confocal imaging: (F, left) Fluar 53/0.25M27 objective; (F, right, G,
ion objective; (I) LD SC Plan-Apochromat 203/1.0 Corr M32 85 mm scale-im-
re S1, S2, and S3 and Tables S1 and S2.
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integrity, and changes in weight and volume during clearing to
ensure that a minimal crosslinking scheme was sufficient to pre-
serve tissue morphology andmolecular information. The amount
of protein that leached out of tissue into SDS clearing buffer was
statistically indistinguishable between 4% PFA-fixed, uncleared
tissue samples (A0P4) that were incubated in PBS as a control,
and cleared tissue-hydrogel matrices prepared with either 4%
acrylamide (A4P0) or with 4% acrylamide plus 4% PFA (A4P4)
(Figure 1C). Notably, the amount of protein recorded in the 8%
SDS clearing bath solutions for all hydrogel-embedded samples
was less than the protein loss (0.57 ± 0.11 mg per mg gross
weight) for the samples preserved only with 4% PFA and incu-
bated in PBS-0.1% Triton X-100, a mild detergent-containing
buffer. This implies that hydrogel monomers effectively crosslink
and stabilize tissue protein, which is further supported by our
finding that unpolymerized, PFA-fixed tissue incubated in 8%
SDS showed poor protein retention (0.63 ± 0.02 mg protein
loss per mg gross weight) (Figure 1C).
To corroborate these results on the preservation of molecular
content in PACT tissue, the relative levels of native eYFP fluores-
cence were visualized and quantified in PACT brain samples
from Thy1-eYFP transgenicmice.While a decrease inmean fluo-
rescence intensity was observed under both hydrogel formula-
tions (A4P0, A2P0), PACT samples showed comparable total
intensity relative to uncleared tissue (Figure 1D) once the fluores-
cent measurements were normalized for tissue expansion (Fig-
ure S1C). Indeed, tissue-hydrogel matrices that were prepared
using acrylamide alone (A4P0) exhibited tissue weight and vol-
ume changes of 174% and 223%, respectively (Figure 1E),
which were significantly greater than the size changes of A4P4
counterparts. But, upon the transfer of tissue samples from
clearing solution to mounting media, PACT samples shrank
back to their original sizewithin a few hours (Figure S3D). This tis-
sue expansion-contraction has been documented in previous
brain-clearing protocols (Chung et al., 2013; Hama et al., 2011;
Susaki et al., 2014), wherein it was concluded that these size
changes, though suboptimal, did not appear to negatively influ-
ence gross tissue morphology or cellular architecture. To visu-
alize the effect of PFA on crosslink density in the tissue-hydrogel
matrix, which is hypothesized to limit tissue expansion, PACT-
cleared brain slices were imaged via scanning electron micro-
scopy (SEM) (Figure S1B). We noted that A2P0 matrices had
the largest pore sizes, followed by A4P0, while A4P4 had the
smallest visualized pore sizes; pore size directly affects diffusion
rate with faster macromolecular diffusion times in tissue-hydro-
gel matrices with larger pores. Tissue deformity (i.e., expansion
and contraction) during PACT processing and mounting did
not appear to affect the overall cellular organization or protein
content of samples relative to conventional histological process-
ing (Figures 1F–1L). Thus, we selected A4P0 for PACT given its
balance between clearing speed, protein retention, and interme-
diate pore size, which is condusive to macromolecule tissue
penetration during histology.
PACT Reagents Are Compatible with Histology and
Endogenous Fluorochromes
To ensure that the signal intensity from genetically encoded fluo-
rescent proteins was preserved throughout PACT processing,948 Cell 158, 945–958, August 14, 2014 ª2014 Elsevier Inc.1-mm-thick Thy1-eYFP tissue sections were A4P0-hybridized,
PACT-cleared, and imaged using confocal microscopy. Despite
PACT clearing, and importantly, the slow image acquisition time
for thick samples, the genetically expressed eYFP was readily
detected throughout the samples (Figures 1F and 1H). Further-
more, the tissue-hydrogel matrix still permitted uniform Nissl
staining of thick, cleared sections (Figure 1F, compared to un-
cleared 100 mm sections in Figure 1G). The overall tissue archi-
tecture remained constant between cleared and uncleared
sections, as revealed by Nissl staining (red), which assuages
concern that successive swelling and then shrinking of tissue
caused permanent tissue deformity.
Not only were native proteins, including those maintaining the
structural integrity of tissue samples, retained by the tissue-hy-
drogel matrix during clearing (Figures 1C, 1F, and 1H), but also
the cleared tissue blocks were sufficiently macromolecule
permeable to permit labeling of peptidic and nucleic acid epi-
topes using a variety of common histological markers (e.g., anti-
bodies, small-molecules, mRNA probes). For example, aside
fromNissl, 1 mmPACT sections from themouse brain and spinal
cord were immunolabeled with antibodies against tyrosine
hydroxylase (TH) (Figure 1I); glial fibrillary acidic protein
(GFAP), murine immunoglobulin G (IgG), and ionized calcium-
binding adaptor molecule 1 (Iba1) (Figure 1J). These targeted
moieties represent antigens occupying a wide variety of cellular
locations: membrane-localized and cytosolic, neuronal and non-
neuronal antigens. PACT clearing decreased light scattering in
tissue samples such that all labels were easily resolved across
the entire 1 mm section during single-photon fluorescence
imaging.
To confirm that PACT methodologies were effective on major
organs as well, the kidney, heart, lung, and intestine ofmice were
excised, cleared, and labeled with anti-integrin antibodies, acri-
dine orange (AO), and/or SYTO24 (Figure 1K). As observed in the
central organ samples (Figures 1F and 1H–1J), small-molecule
dyes and antibodies alike rapidly diffused through 1- to 3-mm-
thick A4P0-crosslinked and PACT-cleared sections of organ
tissues. While the time for complete immunolabeling of thick
sections depends on several factors, including the tissue type,
hydrogel pore size (Figure S1B), and the extent of lipid removal
(Figures 1A, S1A), we achieved uniform 1 and 2 antibody pene-
tration throughout PACT samples with a 7–12 day incubation.
However, for studies that only require labeling with small-
molecule fluorescent dyes, one may obtain rapid staining of
1–3 mm PACT brain sections with a single overnight to 3 day in-
cubation, respectively. Some tissues were stained even faster:
AO labeling of individual nuclei in unsectioned mouse intestinal
tissue (400 mm thick) was attained in under 1 hr (Figure 1K).
We then determined if PACT can be applied to pathological sam-
ples. Human skin cancer biopsies (Figure S2A) were cleared and
stained with pan-cytokeratin to visualize tumor cells (Figures 1L,
S2B, and S2C). In sum, the entire PACT-cleared tissue blockwas
accessible down to the subcellular level for molecular interroga-
tion using standard immunohistochemical methods and conven-
tional fluorescence microscopy.
To determine if PACT was compatible with established
procedures to visualize single mRNA transcripts, we subjected
PACT-processed tissue to single-molecule fluorescent in situ
hybridization, smFISH (Femino et al., 1998; Raj et al., 2008). The
methodology of smFISH is capable of detecting single RNAmol-
ecules with high specificity in fixed cells, and its high sensitivity
allows for measurements of RNA abundance and subcellular
localization. However, smFISH in tissue sections remains chal-
lenging due to low signal to noise ratio caused by tissue auto-
fluorescence. Herein, b-actin transcripts in 100-mm-thick cleared
mouse brain sections were labeled using 24 Alexa 594-labeled
20-mer oligonucleotide probes toward b-actin mRNA. Tissue
samples were slide-mounted in media containing 4’,6-diami-
dino-2-phenylindole (DAPI) and imaged via single-photon micro-
scopy. b-actin transcripts were indeed retained in the cytoplasm
of neurons throughout PACT and smFISH processing, and single
points of fluorescence could be distinguished despite the high
copy number of b-actin in cells and the considerable thickness
of imaged brain section (Buxbaum et al., 2014; Raj et al., 2008)
(Figure 2A). PACT tissue exhibited significantly increased
contrast of diffraction-limited spots throughout the tissue relative
to uncleared tissue (Figure 2C). We found that smFISH intensity
showed very little difference between PACT cleared and un-
cleared tissue, while background intensity was significantly
reduced (Figures 2A, 2B, 2D and 2E, and S2D). These findings,
taken together with the increase in smFISH signal to noise ratio
seen in PACT-cleared tissues, suggests that background auto-
fluorescence in thick samples is the main factor obscuring
smFISH signal in uncleared tissue.
Recipe for Refractive Index Matching Solution for
Imaging and Long-Term Storage of Cleared Tissue
Effective imaging relies on sample immersion in amountingmedia
that reduces the refractive index (RI) variations within heteroge-
neous tissue and that alleviates the RI mismatch between tissue,
mounting media, and lens immersion media interfaces. In re-
sponse to the prohibitive cost and limited availability of
FocusClear, we formulated an affordable substitute: RIMS, with
an RI appropriate for tissue imaging (RI = 1.38–1.48), biological
safety, and biocompatibility for tissue preservation (see Extended
Experimental Procedures). To test RIMS, PACT-processed sam-
ples were mounted in 80% glycerol, FocusClear, or RIMS, and
then imaged under identical conditions (Figure S3A). RIMS pro-
vided good optical clarity for fluorescence microscopy (Fig-
ure S3C) and caused minimal quenching of the eYFP signal over
a 3 month period (Figure S3E). Since its performance appeared
to be on par with or exceed FocusClear (Figure S3A) and provided
a>10-fold reduction inmountingcosts,RIMSwasemployed for all
subsequent PACT and PARS experiments. The exact RIMS
formulation can be optimized in a case-specific manner depend-
ing on the tissue samples and microscopy set-up (Figure S3B).
Whole-Body Clearing Using the Vasculature in Adult
Rodents
The PACT protocol uses a 4% acrylamide monomer solution to
generate the final tissue hydrogel and results in a good combina-
tion of protein preservation, speed and ease of clearing, and op-
tical clarity. However passive diffusion is slow, prohibitive for
large volume or whole-organism clearing. We also noted that
the acrylamide hydrogels markedly swelled during the deter-
gent-clearing phase (Figures 1A and S1C). These two draw-backs, common to most clearing protocols, prompted us to
develop an alternate methodology to speed up clearing and
also to minimize tissue expansion during clearing. We decided
to utilize the existing vasculature networks, as is done regularly
in cardiac perfusion fixation (Gage et al., 2012; Jonkers et al.,
1984), to introduce agents directly to tissue by performing the
entire fixation and clearing procedure in situ. We term this
method perfusion-assisted agent release in situ (or PARS).
PARS utilizes the intact vasculature of the animal to infuse the
hydrogel monomer and clearing solutions directly, which then
diffuse throughout the tissues of interest.
To investigate both whether major blood vessels and whole-
organism microvasculature was accessed by the perfusate
(Leong and Ling, 1990; Li et al., 2012), AlexaFluor 647-conju-
gated antibodies against mouse immunoglobulin (Figure S4B,
right) or Atto 488-conjugated nanobodies against GFAP (Fig-
ure S4B, left) were perfusion recirculated through cardiac cathe-
ters for 24 hr. The mouse brain vasculature was extensively
labeled, illustrating the accessibility of blood vessels to perfusate
(Figure S4B). Perfusate was also observed to diffuse into sur-
rounding tissue, as shown by the extravasculature GFAP label-
ing (Figure S4B, Movie S1).
To perfuse PACT reagents in the cerebrospinal or systemic cir-
culation for several days-to-weeks, we developed a closed-
loop perfusion system. Using this custom PARS chamber
(Figure S4A), continuous intracranial perfusion of 8% SDS into
cerebrospinal fluid (CSF), via a method we termed PARS-CSF
(Figure 3), attained modest whole-brain clearing in as little as 4
days (Figures 3A and 3B). Inserting the cannula more caudally
above the inferior colliculus (Figure 3A, right) granted clearing
of the entire length of the rat spinal cord in 2 weeks (Figure 3B).
Next, AAV9-eGFP injected adult mice were prepared with a sub-
dural cannula inserted directly above the olfactory bulb (Fig-
ure 3A, left), and after 4 days of recirculating 8% SDS at 37 C,
both unmyelinated and densely myelinated mouse brain regions
near CSF circulation (most parts of the cortex, hypothalamus, re-
gions near the ventricles and spinal cord) were transparentized.
GFP-labeling of individual neurons, neuronal processes, and
glial cells was clearly visible throughout the brain (Figure 3C).
Herein, we surmised that the same perfusion-clearing
method of PARS-CSF could be extended to clearing whole-
bodies in situ. Furthermore, the application of a pressure
gradient on tissue during the lipid extraction and antibody diffu-
sion, respectively, might hold the added benefit of accelerating
the clearing and immunolabeling steps relative to PACT-based
clearing of individual excised whole-organs. Clearing reagents
were cycled through systemic circulation (see timeline, Fig-
ure 4A), with complete clearing of all major organs and of
central nervous system accomplished within 1 week and
2 weeks, respectively, for mice and rats alike (Figures 4B–4D
and S7). The minimal protein content of the PARS perfusate,
and the higher protein content of perfusate from A0P4-infused
mice (Figure 4E) suggested that the whole-organism hydrogel
matrix was both necessary and sufficient to stabilize gross
organ structure and macromolecular content. To confirm that
PARS was compatible with visualizing localized fluorescent
protein expression in sparsely labeled cells in multiple organs,
we delivered a GFP transgene by systemic administration ofCell 158, 945–958, August 14, 2014 ª2014 Elsevier Inc. 949
Figure 2. Detection of Individual mRNA Transcripts in PACT Tissue Sections by smFISH
(A and B) 100-mm-thick mouse brain slices were hybridized with twenty-four 20-mer oligonucleotide probes toward b-actinmRNA labeled with Alexafluor 594. (A)
PACT-cleared smFISH brain slices. Top shows 30 mm maximum intensity projection. An abundant number of diffraction limited spots corresponding to single
b-actin mRNAs (red) were readily detected up to 30 mm in depth under 589 nm illumination. Note bright amorphous granules (yellow) are background lipofuscin
vesicles that show up in both 589 nm (red) and 532 nm autofluorescence (green) channels, whereas smFISH signals are in the red channel only.(B) Compared to
PACT-cleared slices, smFISH in uncleared brain slices showed significantly decreased contrast. (Bottom in A and B show single slices of 0.5 mm at 12 mmdepth;
the images were processed from raw data using the same contrast scale and Laplacian of Gaussian filtering; for raw data see Figure S2D).
(C) Signal to noise ratio as a function of depth shows PACT-clearing tissue increases the signal to noise ratio of smFISH throughout the thickness of the sample as
compared to uncleared tissue.
(D) smFISH intensities show no appreciable differences between uncleared and PACT-cleared tissue. p = 0.8722; 2-tailed Student’s t test.
(E) Comparison of background intensity between uncleared and PACT-cleared tissue illustrates the significant reduction of background fluorescence in PACT-
cleared tissue.
p = 0.0006; 2-tailed Student’s t test. All graphs are shown in mean ± SEM. Imaging set-up: (A and B) samples imaged on a Nikon Ti Eclipse microscope with an
Andor Ikon-M camera and a 603/1.4NA Plan Apo l objective with an additional 1.53 magnification. Images acquired as Z-stacks with a 0.5 mm step size over
30 mm. Samples were excited by a 640 nm Coherent Cube, and 532 nm (SDL-532-200TG) and 405 nm(SDL-405-LM-030) lasers.adeno-associated virus (AAV). AAV9:CAG-eGFP (Figure 5D) or
AAV9BD1:CAG-eGFP, a variant of AAV9 that transduces CNS
neurons to a similar extent as AAV9, but exhibits reduced
astrocyte and hepatocyte transduction (Figure 5E) was
delivered via the vasculature in adult mice. In both the brain
and the liver, native eGFP expression was readily detectable
and the reduced transduction of liver hepatocytes by AAV9BD1950 Cell 158, 945–958, August 14, 2014 ª2014 Elsevier Inc.as compared with AAV9 was easily detected (Figures 5E
versus 5D).
In comparison to PACT, we predicted that tissue volume
changes during PARS processing would be reduced since
musculoskeletal structures, such as the skull, the vertebral
column, and muscle walls, would physically constrain tissue
expansion. Indeed, PARS-based clearing of rodent brains was
Figure 3. PARS-CSF: A Protocol for Rapid
Brain or Spinal Cord Clearing and Labeling
via the Cerebrospinal Fluid Circulation
Using Perfusion-Assisted Agent Release In
Situ
(A) CNS tissue may be rendered optically trans-
parent by the direct perfusion of all PACT reagents
into the CSF via an intracranial brain shunt
inserted either (left) below the dura in the region
directly above the olfactory bulb, or (right) placed
directly above the dorsal inferior colliculus. The
cannula, which is connected to the perfusion
lines may be cemented into position with dental
acrylic.
(B) Whole-brain and the corresponding 2-mm-
thick slices (left) and whole-spinal cord (right) from
PARS-CSF rats that were cleared at 37C for
4 days (brain) or for 2 weeks (spinal cord) are
shown. The extent of whole-brain clearing is
dependent on brain tissue proximity to the can-
nula: the frontal lobe was rendered optically
transparent, whereas the midhind brain were only
weakly cleared (see 2 mm slices on right side of
panel). After 24 hr incubation in RIMS, PARS-CSF
brain slices were sufficiently cleared for imaging
without further sectioning.
(C) Images show native eGFP fluorescence in
500 mm PARS-CSF-cleared coronal brain slices
prepared from mice that, 6 months prior to
clearing, received IV injections with AAV9:CAG-
eGFP. Representative sections of cortex and
hippocampus are presented at higher magnifica-
tion in image boxes (right). In the layer V coronal
view, an AAV9 transduced eGFP-expressing glial
cell and eGFP-neuron adjacent to a blood vessel
are clearly visible. In the hippocampus (bottom),
the finer neuronal processes of eGFP-expressing
CA1 neurons may be visualized with high resolu-
tion, which suggests that PARS-CSF may be
completed without severe damage to cellular
morphology.
Objectives used for confocal imaging: (C) LD LCI
Plan-Apochromat 25x/0.8 Imm Corr DIC M27
multi-immersion objective. Also see Figure S4.accomplished with limited hydrogel swelling and tissue expan-
sion during clearing (Figures 4C and 4D and S5A). Although
PARS-processed brains do swell slightly following their extrac-
tion from the skull and placement in PBS or RIMS (Figure S5A),Cell 158, 945–958there was no evidence to suggest that
gross changes in neuronal morphology
occurred as a result of PARS processing
and post-PARS expansion (Figure 5B).
Nevertheless, we attempted to mitigate
tissue swelling in RIMS through postfixing
PARS samples in 4% PFA overnight prior
to RIMS mounting. To assess the extent
to which overall tissue architecture was
altered by volume changes, the intercel-
lular distance and the average cell size
within different brain regions (cortex,
striatum, thalamus) of uncleared, PARS-cleared, and postfixed PARS-cleared samples were measured
(Figure S5B). It was predicted that individual regions may be
differentially affected by PARS processing or RIMS incubation;
for example, any sheer forces originating from perfusion-related, August 14, 2014 ª2014 Elsevier Inc. 951
Figure 4. PARS Achieves Whole-Body Clearing
(A) Schematic of PARS clearing and immunostaining.
(B) A comparison of optical transparency of mouse brains and major organs before and after PARS clearing.
(C) Representative images of relative mouse brain size before (first box, from left) and after (second box) 2 weeks of PARS clearing shows that PARS circumvents
hydrogel swelling and brain tissue expansion during the clearing process. Brain tissue expands gradually after immersion in RIMS (third box); this volume change
may be mitigated via postfixing PARS samples in 4% PFA overnight prior to RIMS mounting (fourth box).
(legend continued on next page)
952 Cell 158, 945–958, August 14, 2014 ª2014 Elsevier Inc.
intracranial pressure may exert a greater insult on less myelin-
ated tissue or cause ventricle collapse. Postfixing PARS samples
significantly prevented the increased cell sizes and intercellular
distances that were detected throughout PARS samples. There
were no significant differences in cell size or intercellular spacing
between uncleared and postfixed samples in all brain regions as-
sayed (Figure S5B).
Whole-Organism PARS Enables Phenotyping and
Imaging in an Organ-by-Organ Fashion
Following whole-body PARS processing and labeling, major
organs were excised, thick-sectioned, and imaged using con-
focal microscopy (Figures 5, 6, and S6). The PARS-cleared
whole brain (Figures 5A and 5B) and spinal cord (Figure 5C)
of Thy1-eYFP mice were imaged, and we concluded that
PARS processing rendered entire organs optically transparent
to the extent that visualizing deep-tissue structures with cellular
resolution was possible. Through visualizing individual neurons
and nephrons throughout the cleared whole-brain (Figures 5A
and 5B; Movie S2) and kidney (Figure 6B; Movie S3), respec-
tively, we may posit that this optical clarity was achieved while
leaving fine cellular structures intact, in part due to the success
of in situ tissue-hydrogel polymerization in stabilizing tissue
architecture, preserving protein content and endogenous fluo-
rescence, and maintaining the spatial relationships between
subcellular and cellular tissue components (Figures 5A and
5B). For example, we could resolve individual fluorescently
labeled glomeruli of individual nephrons within whole-kidney,
which establishes the ability of PARS to access major organs
through intact vasculature (Figures 6B and S6). Importantly,
this includes the delivery of all immunohistochemical solutions
as well, including blocking solutions, primary and fluorescently
labeled secondary antibody cocktails, or fluorescently labeled
small-molecules, and wash buffers. Labeling using PARS was
target-specific, uniformly distributed throughout major organs,
and exhibited low background; this was illustrated by the
anti-tubulin antibody and DRAQ5 labeling in PARS-processed
mouse kidney (Figure 6B, Movie S2) and by the lectin staining
of blood vessel endothelium in the liver, lung, and pancreas
(Figure S6).
DISCUSSION
Herein we introduce PARS, a method that renders intact whole-
organisms transparent for imaging with single-cell resolution
while preserving fluorescent and protein-based signals and tis-
sue architecture. Our starting point, the CLARITY method
(Chung et al., 2013) provided scientists with a brain-processing
platform for elucidating the 3D cellular arrangement and con-
nectome in toto. Numerous laboratories have previously re-
ported on new clearing reagents in the decade before
CLARITY; however, many of these reagents were highly appli-(D) Representative images of relative rat brain size before (right) and after (left) 4 da
rat whole-brain samples show gross tissue morphology, highlighting that unmye
(E) Protein loss of PARS clearing compared to other clearing methods (n = 4 mice
post hoc test was used to determine statistical significance in comparison to A4
Images for (B–D) were taken using bright field camera. Also see Figures S4, S7,cation or tissue specific (summarized in Table S1). In contrast,
CLARITY introduced two broadly applicable techniques per-
taining to tissue preservation (hydrogel embedding) and
clearing efficiency (electrophoretic tissue clearing, ETC), both
of which could be incorporated into the design, or redesign,
of other clearing procedures. Traditionally, making tissue trans-
parent was a process that demanded solvent incubations on
the order of weeks to months, as reported in other clearing pro-
tocols (Hama et al., 2011). ETC, however, challenged the
prevailing view that the rate of tissue clearing could only be
accelerated through assaying large panels of organic solvents
for their ability to solubilize tissue rapidly. Oftentimes, candidate
solvents tested in these screens achieved rapid tissue clearing,
but compromised tissue structure (Hama et al., 2011) or
quenched native fluorescence (Becker et al., 2012; Ertu¨rk
et al., 2012a; Susaki et al., 2014). Although the reagents intro-
duced by CLARITY are gentler by comparison, the needed
ETC step for fast clearing can cause tissue degradation from
sample heating. This risk can be bypassed by the use of pas-
sive CLARITY (Tomer et al., 2014), but again, the slow rate of
clearing makes the technique impractical for scaling up or for
whole-body mapping.
With the goal of rapidly clearing whole organisms while still us-
ing mild detergents and fluorescence nonquenching reagents
throughout, we evolved PARS on the basic principles of
CLARITY, but aimed to bypass the need for ETC while maintain-
ing faster clearing than through passive diffusion. First we opti-
mized the CLARITY agents for passive clearing by removing
bisacrylamide and increasing the detergent concentration to
8% SDS (PACT reagents). The tissue-clearing step was rede-
signed such that the electrophoretic force used by CLARITY to
drive fast lipid extraction was replaced with a perfusion-based
pressure gradient. Controlled flow of PACT reagents throughout
intact tissue vasculature transforms most organs into optically
transparent tissue within 2–3 days, while whole-mouse and
whole-rat brains are rendered transparent within 1–2 weeks.
Additionally, the self-contained nature of clearing in situ also
reduced tissue expansion during monomer infusion and lipid
removal.
PARS opens up the possibility of whole-organ and whole-or-
ganism mapping with high phenotypic content. With this in
mind, quick, low-resolution scanning of large tissue blocks can
direct investigators to restricted areas worthy of slow, high
phenotypic content analysis, including smFISH: a method that
preserves fluorescent markers long-term is particularly valuable
in this respect. Both PACT and PARS methodologies are scal-
able, cost-effective relative to the original CLARITY process
and theoretically transferrable to other model organisms or hu-
man tissue. Indeed, while PARS was depicted using cardiac
perfusion in rodents, the overall methodology may also be appli-
cable to instances in which sufficiently large vessels are available
for creating a perfusion route, such as whole-organ perfusion inys of PARS clearing, showing howPARS is a scalable method. Coronal slices of
linated areas may be cleared within 4 days of PARS-based clearing.
for each); graph shows mean ± SEM; one way ANOVA followed by Bonferroni
P0 8% SDS PARS clearing; *** p < 0.005.
S3E, and Movie S1.
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Figure 5. PARS Enables Whole-Brain Mapping of Widespread and Sparse Genetically Encoded Fluorescent Signals with Subcellular
Resolution
(A and B) Whole-brain image (z = 6 mm) (A), and deep-brain imaging (z = 4 mm) (B) of adult Thy1-eYFP mouse after PARS clearing for 10 days. The boxes on the
right show high-magnification images of indicated areas.
(C) Spinal cord image of adult Thy1-eYFPmouse after PARS clearing for 2 weeks (z = 2 mm). Bottom, high-magnification images of indicated region (z = 1.2 mm).
(D) Images show native eGFP fluorescence in 1 mm coronal brain slices (left) and liver (right) prepared from the PARS-cleared mice that received IV injections of
AAV9:CAG-eGFP. Image columns to the right of each coronal brain image show the orthogonal views (z = 0.5 mm).
(E) Native eGFP fluorescence in 1 mm coronal brain slices (left) and liver (right) prepared from PARS-cleared mice injected with a liver detargeted variant,
AAV9BD1:CAG-eGFP. Image columns to the right of each coronal brain image show the orthogonal views (z = 0.5 mm).
Objectives used for confocal imaging: (A) Fluar 53/0.25 M27 objective; (B) Leica HC FLUOTAR L 253/1.00 IMM CORR objective working distance of 6.0 mm;
(C, Top) Fluar 53/0.25 M27 objective (C, Bottom, inset) LD LCI Plan-Apochromat 253/0.8 Imm Corr DIC M27 multi-immersion objective; (D–E) LD LCI Plan-Apo-
chromat 253/0.8 Imm Corr DIC M27 multi-immersion objective. Also see Figure S5 and Movie S2 (for 5B).
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Figure 6. PARS Allows Rapid and Uniform Clearing and Immunolabeling of Major Organs
(A andB) Clearing and immunohistochemical labeling was achieved inwholemice through PARS alone. (A) PARS-clearedmouse intestine was stainedwith lectin,
methylene blue, and DAPI, and imaged through a depth of 500 mm. Bottom row, maximum intensity projection of slice outlined within top-right rendering.
z = 50 mm. (z = 500 mm). (B) A whole kidney was imaged (left) for anti-tubulin antibody and DRAQ5 labeling. High-magnification images (right) of the indicated
region and the structure of glomeruli, demonstrating that PARS enables antibody-based labeling throughout the kidney (z = 1.2mm). Objectives used for confocal
imaging: (A) Zeiss LSM 780 confocal microscope with the 103 0.45 N.A. Plan-Apochromat; (B) LD SC Plan-Apochromat 203/1.0 Corr M32 85 mm scale-
immersion objective (working distance 5.6 mm, Zeiss). Also see Figure S6, S7, and Movie S3 (for 6B).
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larger, higher-order mammals, including isolated human tissue.
While PARS does achieve increased speed of clearing and
reduced swelling without tissue damage (Table S1) themethod’s
unique strength lies in its scalability. Our data demonstrate, for
example, that PARS can be employed to assess AAV-mediated
transduction at the cellular level in multiple organs after systemic
delivery. By eliminating the need to section individual tissues, the
PARS approach could expedite efforts to screen numerous AAV
serotypes and/or gene regulatory elements for optimal expres-
sion in the cell types of interest. In addition to improving
screening throughput and speed, a PARS-based whole-body
method could also counteract the risk of underestimating AAV
transduction in target tissues due to undersampling errors.
PARS holds the potential to refine our understanding of pe-
ripheral nerves at their target whole organs. Accurate maps of
complex long-range fiber bundles, such as for the vagus nerve
(George et al., 2000), could help inform improvements in existing
therapies or spur the development of entirely novel therapeutic
strategies, such as for bioelectronic medicines (Famm et al.,
2013). Expanding this strategy out to the level of body-brain in-
terconnections, PARS may facilitate biomedical work in whole-
body screening experiments for off- and on-target agents, and
for sparse elements such asmetastatic tumor cells or stem cells.
Lastly, the PARSmethod is compatible with cell-filling endoskel-
etal structures. By combining PARS with TEMPEST—a precur-
sor to CLARITY (Deisseroth and Gradinaru, 2012)—the in vivo
expression of long-lasting keratin filaments (that outlive the cells
themselves while keeping a loyal blueprint of the morphology)
within populations of interest can facilitate accurate postmortem
quantification and mapping of long-degenerated cells
throughout the brain.
The methods introduced here build upon our prior work using
CLARITY to expand tissue clearing and phenotyping towhole or-
ganisms by using the intrinsic circulatory systems. Because the
vascular network is not homogeneous, leading to nonuniform
perfusive flow, organs of interest will clear at different rates. To
achieve optimal clearing while retaining high tissue content,
further validation for specific applications and technical improve-
ments will be necessary. The blood-brain barrier may present a
challenge to efficient perfusion-based transport of particularly
large molecules such as antibodies (150 kDa) to the brain relative
to the other organs. To improve perfusion efficiency, one likely
solution will be to engineer (or utilize when already available)
smaller antibody scaffolds for immunolabeling; these include
the fragment-antigen-binding format of immunoglobulins (Fab
50 kDa), and nanobodies, single domain antibodies derived
from camelid antibodies, whose smaller size (12–15 kDa) pro-
motes tissue permeability (Harmsen and De Haard, 2007).
Improved imaging platforms will be needed to take full advan-
tage of all the recent tissue-clearing work, ours and others
(Becker et al., 2012; Chung et al., 2013; Dodt et al., 2007; Ertu¨rk
et al., 2012a; Ertu¨rk and Bradke, 2013; Hama et al., 2011; Ke
et al., 2013; Kuwajima et al., 2013; Susaki et al., 2014). In order
to obtain cellular and subcellular information in thick cleared tis-
sue, it is necessary to utilize long-working distance, high numer-
ical aperture, multi-immersion objectives. Scanning speed is an
additional barrier with cleared tissue blocks taking many days to
be fully imaged—resonant scanners or light-sheet microscopy956 Cell 158, 945–958, August 14, 2014 ª2014 Elsevier Inc.(Tomer et al., 2014) can accelerate the process while retaining
high-resolution data.
Given increasing interest in the link between the brain and
major organ systems (Birmingham et al., 2014), it will be critical
to have an unsegmented view of the whole body, with structural
connections between the brain and other major organs left
intact. The combination of PARS with enabling technologies
(nanobodies, imaging platforms) will not only advance neurosci-
entists’ overarching goal of creating a brain connectome, but it
also has the potential to facilitate mapping the broader brain-
to-body-and-back connectome and phenotyping other organ
systems in the body, healthy or diseased.
EXPERIMENTAL PROCEDURES
PACT Clearing
Four percent paraformaldehyde (PFA)-fixed tissue sections were incubated at
4C overnight in the hydrogel monomer solution A4P0 (4% acrylamide in PBS)
supplemented with 0.25% photoinitiator 2,20-Azobis[2-(2-imidazolin-2-yl)
propane]dihydrochloride (VA-044, Wako Chemicals USA). A4P0-infused sam-
ples were degassed with nitrogen for 1–5 min and then incubated for 2–3 hr at
37C to initiate tissue-hydrogel hybridization. After removing excess hydrogel
via brief PBS washes, tissue-hydrogel matrices were transferred into 50 ml
conical tubes containing 8%SDS in 0.1 M PBS (pH 7.5), and depending on tis-
sue size, were incubated for 2–5 days at 37C with shaking. For immunostain-
ing, 1- to 3-mm-thick PACT-processed samples were washed in PBS with 4–5
buffer changes over the course of a day and then transferred to buffer contain-
ing small-molecule dyes or primary antibodies followed by fluorescently con-
jugated secondary antibody (1:200–400, in PBS containing 2% normal donkey
serum, 0.1% Triton X-100 and 0.01% sodium azide) for 3–7 days or with small-
molecule dyes for 1–3 days. Antibody or small-molecule dye solutions need to
be replaced every day. Unbound antibody was removed via PBS washes, as
before, and then samples were incubated with secondary antibodies (Fab
fragment secondary antibodies are preferred, 1:200–400) for 2–5 days then
washed for 1 day in PBS or phosphate buffer (PB) prior to incubation in imaging
media (RIMS). All staining and mounting steps were conducted at room tem-
perature with gentle shaking.
RIMS Imaging Media with RI 1.46
Forty grams of Sigma D2158 (Histodenz) in 30 ml of 0.02 M PB with 0.1%
tween-20 and 0.01% sodium azide, pH to 7.5 with NaOH—which results in a
final concentration of 88%Histodenz w/v. Samples are incubated in RIMS until
transparent (1 day for PACT samples, up to 1 week for PARS-cleared brains),
followed by mounting in fresh RIMS.
smFISH
One hundred micrometer PACT sections were ethanol-permeabilized, labeled
with 24 Alexa 594-labeled 20-mer oligo probes toward b-actin (overnight
incubation at 37C), washed, and coverslipped with Slowfade Gold + DAPI ac-
cording to published protocols (Buxbaum et al., 2014; Lyubimova et al., 2013).
Laplacian of Gaussian filtering with a radius of 3 was applied to visualize tran-
scripts in both cleared and uncleared samples.
PARS Protocol
Immediately following standard cardiac perfusion with 4% PFA (in PBS, pH
7.5), the fixed rodent was transferred onto a perfusion chamber (Figure S4A)
which recirculated all subsequent PACT and immunolabeling reagents (as
above) continuously (1 ml/min) through rodent vasculature via a peristaltic
pump. Perfusion tubing connected the chamber to a feeding needle inserted
through the left ventricle into the aorta and loosely sutured in place. The rodent
was postfixed with 4% PFA for 1 hr and then perfusion washed with PBS for
1 hr. A4P0 monomer was cycled through vasculature overnight, followed by
a 2 hr PBS perfusion wash. Before polymerization and without disconnecting
perfusion lines, the perfusion chamber was placed into a ziplock bag (Fig-
ure S4A), and the bag containing the chamber with rodent was degassed for
2 min under nitrogen gas. Polymerization was initiated via perfusion recircula-
tion of 200 ml of 0.25% VA-044 initiator in PBS at 37C for 2–3 hr. The whole-
bodywas cleared through a%2week perfusionwith 8%SDS in PBS, pH 7.5 at
37–42C followed by extensive PBS perfusion washing over 2–3 days. Anti-
bodies and small-molecule dyes (as above in PACT) were then delivered via
a 3 day perfusion and 1 day wash.
For the PARS-CSF variation of brain or spinal cord clearing (Figures 3A and
3B), transcardially-fixed rodents were decapitated and a subdural cannula
was inserted above the region of interest and cemented to the skull. All
PACT reagents are delivered in the same order and timeframe as PARS at
1 ml/min.
AAV Production and Systemic Delivery
Single-stranded ssAAV-CAG-eGFP vectors packaged into AAV9 or the AAV9
variant capsid, AAV2/9BD1, was generated and purified as described (Lock
et al., 2010). The AAV2/9BD1 capsid was modified from AAV2/9 (U. Penn)
with, among others, an N498Ymutation to reduce liver transduction (Pulicherla
et al., 2011); 1 3 1012 vector genomes (vg) of either virus was delivered intra-
venously into mice and tissue assessed 6 months later by PARS for native
eGFP fluorescence.
Fluorescence Microscopy
Cleared tissue samples were mounted in RIMS at room temperature using
spacers from 0.5–7 mm depending on sample thickness (iSpacer, SunJin
Lab; Silicone Isolator, Electron Microscopy Sciences, PA) and coverslipped.
For Figure 3B, the samples were imaged by Leica Microsystems using a Leica
TCS SP8 two-photon microscope with the Leica HC FLUOTAR L 253/1.00
IMM CORR objective (working distance, w.d. 6.0 mm). Other images
were taken using a Zeiss LSM 780 confocal microscope with either the Fluar 5
3/0.25 M27 objective (w.d. 12.5 mm), Plan-Apochromat 103/0.45 M27 objec-
tive (w.d 2.0 mm), LD SC Plan-Apochromat 203/1.0 Corr M32 85 mm scale-
immersion objective (w.d. 5.6 mm), or LD LCI Plan-Apochromat 253/0.8
Imm Corr DIC M27 multi-immersion objective (w.d 0.57 mm). Image recon-
structions were performed using Imaris imaging software (Bitplane). After im-
aging, samples were stored in RIMS at room temperature.
For more detailed methods see Extended Experimental Procedures and
Table S2 for a detailed list of reagents/buffers.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
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